 |
| via |
Compared to standard single vision lenses, Essilor Stellest lenses slowed myopic prescription progression and axial length progression. Back in 2021 the lens was submitted to the FDA and granted "Breakthrough Device Status" but has still not received FDA approval as of the writing of this article. Since that time, continued studies in countries where the lens is available have reported data. The latest is a 6 year study just released from China:
The study began in 2018 with children aged between 8 and 13 years old. After completing the initial five-year study phase, participants continued wearing Essilor Stellest lenses for an additional two years to assess the long-term impact on myopia progression.
- The six-year results showed that Essilor Stellest lenses slowed prescription progression by 1.95 D (57% prescription progression reduction) and slowed axial elongation by 0.81 mm (52% axial length progression reduction)
- Risk of progressing to high myopia (defined as -6.00D or worse) dropped from 38% in the single-vision lens control group to just 9% in the Essilor Stellest lenses group
No word yet as to when the FDA decision for approval will come for the USA, but the body of evidence that myopia management glasses can reduce childhood myopia is only growing!
_SAND.jpg)
